Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy on December 02, 2025 alpha 1-Antitrypsin Deficiency gene therapy gene writing Investments Partnership Regeneron Tessera TSRA-196 +
Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships on December 01, 2025 alpha 1-Antitrypsin Deficiency ARPA-H grant CAR-T Clinical Trials Gene Writing genome engineering in vivo Lipid Nanoparticles Partnership Regeneron Tessera TSRA-196 +